Novo Nordisk has announced a major restructuring, cutting 9,000 jobs in response to slowing sales and heightened competition in obesity and diabetes markets. The company has also mandated full-time office returns for staff, aiming to enhance collaboration and decision-making under new leadership. This shift follows broader industry trends where firms recalibrate operations amid evolving commercial dynamics.